Clinical trial
Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived…
NCT00005903 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00005903 |
|---|---|
| Title | Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy |
| Official title | Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Progressive Supranuclear Palsy |
| Intervention type | Drug |
| Interventions | GDNF & Synchro Med Infusion System |
| Enrollment | 15 |
| Start date | Jun 1, 2000 |
| Completion | May 1, 2005 |
| First posted | Jun 8, 2000 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: